The hosts discuss AI's growing impact across various sectors, from pharmaceutical advancements to creative advertising and defense technology. They analyze Novartis' acquisition of Excellergy for its allergy drug research, highlighting the biotech playbook and AI's role in streamlining FDA filings. The conversation shifts to Anthropic's new Mythos model, debating its potential and the compute constraints facing AI development. They also cover the preliminary injunction granted to Anthropic regarding Pentagon supply chain risk designation. The hosts then explore real estate trends, including the appeal of apres-ski bars and celebrity home listings, before interviewing guests about AI-driven design tools and defense applications.
Sign in to continue reading, translating and more.
Continue